![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma
Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma
![KitePharma_Logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/KitePharma_Logo.png?t=1582159316&width=430)
The UK’s National Institute for Health and Care Excellence (NICE) says certain patients with mantle-cell lymphoma can be considered for treatment with Tecartus, a personalized therapy developed by Kite Pharma, a Gilead Sciences subsidiary.
NICE says the treatment can be considered for patients with relapsed or refractory mantle-cell lymphoma who previously received a Bruton’s tyrosine kinase inhibitor, such as ibrutinib, and it is recommending the therapy for use by the National Health Service.
Tecartus is a CAR-T therapy that uses a patient’s white blood cells as modified in a laboratory to attack cancer cells before being infused back into the patient.
Upcoming Events
-
21Oct